Aspen Aerogels, Inc. cash flow to debt ratio of 22.87% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aspen Aerogels, Inc.'s free cash flow has increased -88.76% from $-40.71M last year to $-4.58M, signaling increasing performance

Aspen Aerogels, Inc.'s debt to equity ratio is 0.60, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Aspen Aerogels, Inc.'s debt has increased relative to shareholder equity from 0.32 last year to 0.60 today, signaling weakened financials

Aspen Aerogels, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Aspen Aerogels, Inc.'s interest coverage ratio of 40.61 indicates that earnings with good margin can cover interest payments on company debt

Aspen Aerogels, Inc.'s profit margin has decreased (-1.75K%) in the last year from 2.95% to -48.64%, signaling decreasing performance

Aspen Aerogels, Inc.'s short-term assets of $242.05M exceed its short-term liabilities of $62.02M

Aspen Aerogels, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aspen Aerogels, Inc.'s return on equity of -42.12%, is lower than 15.00%, indicating bad performance

Aspen Aerogels, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aspen Aerogels, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Aspen Aerogels, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aspen Aerogels, Inc. has negative free cash flow, indicating cash burn

Aspen Aerogels, Inc.'s yearly earnings has decreased -3.01K% since last year from $13.38M to $-389.55M, signaling decreasing performance

Aspen Aerogels, Inc.'s yearly revenue has decreased -40.11% since last year from $452.70M to $271.10M, signaling decreasing performance

ROIC 63.75% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Aspen Aerogels, Inc.'s 3-year revenue CAGR of 14.55% is positive, indicating growing revenue over the past 3 years

Aspen Aerogels, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Aspen Aerogels, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Aspen Aerogels, Inc. has insufficient data to evaluate this check.

Aspen Aerogels, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aspen Aerogels, Inc. is undervalued relative to its fair value price of 483.22 based on EBITDA multiple model

Aspen Aerogels, Inc. has an EV/EBITDA ratio of 0.07x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Aspen Aerogels, Inc. is overvalued relative to its fair value price of -13.08 based on Earnings Fair Value model

Aspen Aerogels, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aspen Aerogels, Inc. has a price-to-book ratio of 2.04x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aspen Aerogels, Inc. has a price-to-sales ratio of 1.89x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue